Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib.
Allen Chung-Cheng HuangChi-Hsien HuangChien-Ying LiuStelios PavlidisHo-Wen KoFu-Tsai ChungTin-Yu LinChih-Liang WangYi-Ke GuoCheng-Ta YangPublished in: Targeted oncology (2020)
Acquired T790M fraction of EGFR-mutated NSCLC is linked to different generations of prior EGFR TKI use and the later efficacy of osimertinib.